|
gptkbp:instanceOf
|
antipsychotic medication
phenothiazine derivative
|
|
gptkbp:affiliatedWith
|
typical antipsychotics
|
|
gptkbp:ATCCode
|
N05AC02
|
|
gptkbp:brand
|
Mellaril
|
|
gptkbp:CASNumber
|
50-52-2
|
|
gptkbp:color
|
yellowish powder
|
|
gptkbp:contraindication
|
severe cardiac disorders
concomitant use with drugs that prolong QT interval
|
|
gptkbp:discoveredBy
|
Ernst Boehringer
|
|
gptkbp:eliminationHalfLife
|
6-8 hours
|
|
gptkbp:hasMolecularFormula
|
C21H26N2S2
|
|
gptkbp:hasSMILES
|
CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
thioridazine
|
|
gptkbp:introducedIn
|
1959
|
|
gptkbp:IUPACName
|
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanyl-phenothiazine
|
|
gptkbp:KEGGID
|
D00367
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:MeSH_ID
|
D013849
|
|
gptkbp:metabolism
|
liver
mesoridazine
sulforidazine
|
|
gptkbp:molecularWeight
|
370.6 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1082
5452
5251
DB00679
|
|
gptkbp:receptorAntagonist
|
gptkb:muscarinic_acetylcholine_receptor
gptkb:alpha-adrenergic_receptor
antihistamine
dopamine D2 receptor
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
QT prolongation
hypotension
sedation
tardive dyskinesia
anticholinergic effects
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:UNII
|
M4P9G02F6X
|
|
gptkbp:usedFor
|
schizophrenia
psychotic disorders
|
|
gptkbp:withdrawn
|
gptkb:Canada
gptkb:United_States
|
|
gptkbp:withdrawnReason
|
risk of cardiac arrhythmias
|
|
gptkbp:bfsParent
|
gptkb:Vivitrol
gptkb:CYP2D6_gene
gptkb:KCNH2
|
|
gptkbp:bfsLayer
|
7
|